Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989;8:943–50.

Article  CAS  PubMed  Google Scholar 

Stefani S, Goglio A. Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance. Int J Infect Dis. 2010;14(Suppl 4):S19-22.

Article  PubMed  Google Scholar 

Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003;111:1265–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest. 2014;124:2836–40.

Article  PubMed  PubMed Central  Google Scholar 

Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23:99–139.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schriever CA, Fernández C, Rodvold KA, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm. 2005;62:1145–58.

Article  CAS  PubMed  Google Scholar 

Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal β-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Werth BJ, Ashford NK, Penewit K, et al. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2021;27(910):e1-910.e8.

Google Scholar 

Mishra NN, McKinnell J, Yeaman MR, et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2011;55:4012–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang S-J, Kreiswirth BN, Sakoulas G, et al. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis. 2009;200:1916–20.

Article  CAS  PubMed  Google Scholar 

Sakoulas G, Rose W, Rybak MJ, et al. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J Clin Microbiol. 2008;46:220–4.

Article  CAS  PubMed  Google Scholar 

Cui L, Tominaga E, Neoh H, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55(Suppl 2):ii15-20.

Article  CAS  PubMed  Google Scholar 

Malabarba A, Nicas TI, Thompson RC. Structural modifications of glycopeptide antibiotics. Med Res Rev. 1997;17:69–137.

Article  CAS  PubMed  Google Scholar 

Dash RP, Babu RJ, Srinivas NR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis (Lond). 2017;49:483–92.

Article  PubMed  Google Scholar 

Xhemali X, Smith JR, Kebriaei R, et al. Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus. J Antimicrob Chemother. 2019;74:82–6.

CAS  PubMed  Google Scholar 

Kebriaei R, Rice SA, Stamper KC, Rybak MJ. Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic/pharmacokinetic model. Antimicrob Agents Chemother. 2019;63:e01743-18. https://doi.org/10.1128/aac.01743-18.

Abdul-Mutakabbir JC, Kebriaei R, Stamper KC, et al. Dalbavancin, vancomycin and daptomycin alone and in combination with cefazolin against resistant phenotypes of Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antibiotics. 2020;9:696.

Article  CAS  PubMed  PubMed Central  Google Scholar 

CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition. Clinical & Laboratory Standards Institute. M100. 2020. https://clsi.org/all-free-resources/. Accessed 1 Apr 2020.

Kebriaei R, Rice SA, Singh NB, et al. Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights. J Antimicrob Chemother. 2020;75:2894–901.

Article  CAS  PubMed  Google Scholar 

Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008;46:577–83.

Article  CAS  PubMed  Google Scholar 

Smith JR, Roberts KD, Rybak MJ. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against gram-positive infections. Infect Dis Ther. 2015;4:245–58.

Article  PubMed  PubMed Central  Google Scholar 

Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anon. easySpiral Dilute—Dilutor and plater | INTERSCIENCE. https://www.interscience.com/en/products/automatic-platers/easyspiral-dilute. Accessed 31 Jul 2023.

Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991;35:2505–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48:4665–72. https://doi.org/10.1128/AAC.48.12.4665-4672.2004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kebriaei R, Rice SA, Stamper KC, et al. Daptomycin dose-ranging evaluation with single-dose versus multidose ceftriaxone combinations against Streptococcus mitis/oralis in an ex vivo simulated endocarditis vegetation model. Antimicrob Agents Chemother. 2019. https://doi.org/10.1128/AAC.00386-19.

Article  PubMed  PubMed Central  Google Scholar 

Kebriaei R, Rice SA, Singh KV, et al. Influence of inoculum effect on the efficacy of daptomycin monotherapy and in combination with β-lactams against daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/AAC.00315-18.

Article  PubMed  PubMed Central  Google Scholar 

Cojutti PG, Rinaldi M, Zamparini E, et al. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections. Antimicrob Agents Chemother. 2021;65:e02260-e2320.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wenisch JM, Meyer B, Fuhrmann V, et al. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2012;67:977–83.

Article  CAS  PubMed  Google Scholar 

Lenhard JR, Bulman ZP. Inoculum effect of β-lactam antibiotics. J Antimicrob Chemother. 2019;74:2825–43. https://doi.org/10.1093/jac/dkz226.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brook I. Inoculum effect. Rev Infect Dis. 1989;11:361–8.

Article  CAS  PubMed  Google Scholar 

Loffredo MR, Savini F, Bobone S, et al. Inoculum effect of antimicrobial peptides. 2020: 2020.08.21.260620. https://doi.org/10.1101/2020.08.21.260620v1.

Kussmann M, Obermueller M, Berndl F, et al. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model. Sci Rep. 2018;8:9661.

Article  PubMed  PubMed Central  Google Scholar 

Ramdeen S, Boucher HW. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2015;16:2073–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aktas G, Derbentli S. In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains. J Antimicrob Chemother. 2017;72:441–3.

Article  PubMed  Google Scholar 

Belley A, Lalonde Seguin D, Arhin F, Moeck G. Comparative in vitro activities of oritavancin, dalbavancin, and vancomycin against methicillin-resistant Staphylococcus aureus isolates in a nondividing state. Antimicrob Agents Chemother. 2016;60:4342–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gatti M, Andreoni M, Pea F, Viale P. Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs. DDDT. 2021;15:3349–78.

Article